Literature DB >> 11252588

Bayesian inference on protective antibody levels using case-control data.

V J Carey1, C J Baker, R Platt.   

Abstract

In the study of immune responses to infectious pathogens, the minimum protective antibody concentration (MPAC) is a quantity of great interest. We use case-control data to estimate the posterior distribution of the conditional risk of disease given a lower bound on antibody concentration in an at-risk subject. The concentration bound beyond which there is high credibility that infection risk is zero or nearly so is a candidate for the MPAC. A very simple Gibbs sampling procedure that permits inference on the risk of disease given antibody level is presented. In problems involving small numbers of patients, the procedure is shown to have favorable accuracy and robustness to choice/misspecification of priors. Frequentist evaluation indicates good coverage probabilities of credibility intervals for antibody-dependent risk, and rules for estimation of the MPAC are illustrated with epidemiological data.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11252588     DOI: 10.1111/j.0006-341x.2001.00135.x

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  4 in total

1.  Augmented designs to assess immune response in vaccine trials.

Authors:  Dean Follmann
Journal:  Biometrics       Date:  2006-12       Impact factor: 2.571

2.  Maternal antibody at delivery protects neonates from early onset group B streptococcal disease.

Authors:  Carol J Baker; Vincent J Carey; Marcia A Rench; Morven S Edwards; Sharon L Hillier; Dennis L Kasper; Richard Platt
Journal:  J Infect Dis       Date:  2013-10-16       Impact factor: 5.226

3.  Estimation of invasive Group B Streptococcus disease risk in young infants from case-control serological studies.

Authors:  Alane Izu; Fabio Rigat; Gaurav Kwatra; Shabir A Madhi
Journal:  BMC Med Res Methodol       Date:  2022-03-27       Impact factor: 4.615

Review 4.  Advances towards licensure of a maternal vaccine for the prevention of invasive group B streptococcus disease in infants: a discussion of different approaches.

Authors:  Judith Absalon; Raphael Simon; David Radley; Peter C Giardina; Kenneth Koury; Kathrin U Jansen; Annaliesa S Anderson
Journal:  Hum Vaccin Immunother       Date:  2022-03-03       Impact factor: 4.526

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.